Form 4: Eli Lilly CEO Ricks Acquires LLY Shares

Eli Lilly's President, Chair, and CEO, David A. Ricks, acquired 38,913.584 shares of common stock in a pre-planned transaction.

Summary

• David A. Ricks, President, Chair, and CEO of Eli Lilly & Co., acquired 38,913.584 shares of common stock.
• The transaction occurred on February 9, 2026, at a price of $1,044.67 per share.
• This acquisition was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Ricks directly beneficially owns 571,715.097 shares of common stock.
• Indirect holdings include 6,685 shares via David A. Ricks 2025 GRAT, 54,117 shares via David A. Ricks 2022 GRAT, 300 shares via Trust, 68,656 shares via David A. Ricks SLAT, and 7,307.91 shares in a 401(k).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive signal, as a significant share acquisition by the CEO, even if pre-planned, demonstrates strong conviction in the company's value and future growth.

Positives

• The CEO's acquisition of a significant number of shares (38,913.584) at a price of $1,044.67 per share demonstrates continued confidence in Eli Lilly's future performance.
• The transaction increases the CEO's direct beneficial ownership to 571,715.097 shares, aligning management's interests further with shareholders.

Negatives

• No specific negative points are identified in this Form 4 filing, which reports an acquisition.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a CEO, can often be interpreted by the market as a positive signal, suggesting management's belief in the company's future prospects. This transaction occurs within the highly competitive pharmaceutical and biotechnology industry, where executive confidence can influence investor sentiment.

Comparison to Industry Standards

• This filing reports an insider transaction, which is standard practice for executives of publicly traded companies.
• The acquisition of shares by a CEO is generally viewed favorably, aligning with best practices for executive compensation and incentivization, similar to how executives at Pfizer or Johnson & Johnson might increase their holdings.

Stakeholder Impact

• Shareholders: The acquisition by the CEO may instill greater confidence among shareholders, signaling strong internal belief in the company's trajectory.
• Employees: May view the CEO's increased stake as a sign of stability and long-term commitment to the company's success.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

While the CEO's acquisition of shares is a positive indicator of confidence, this Form 4 filing alone does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' recommendation. It confirms insider alignment but does not alter the fundamental investment thesis for Eli Lilly, hence a 'hold' is appropriate for investors awaiting broader company updates.

Keywords

Eli Lilly, LLY, David A. Ricks, Insider Trading, Form 4, Stock Acquisition, CEO, Pharmaceuticals, Biotech, 10b5-1 Plan